SG Americas Securities LLC increased its position in shares of Cambrex Co. (NYSE:CBM) by 249.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,181 shares of the biotechnology company’s stock after purchasing an additional 39,376 shares during the period. SG Americas Securities LLC owned 0.16% of Cambrex worth $2,084,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the stock. Raymond James & Associates bought a new position in shares of Cambrex during the 2nd quarter valued at approximately $262,000. Millennium Management LLC bought a new position in shares of Cambrex during the 2nd quarter valued at approximately $5,150,000. Bank of New York Mellon Corp grew its stake in shares of Cambrex by 3.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,471,966 shares of the biotechnology company’s stock valued at $76,982,000 after acquiring an additional 54,475 shares during the period. Northern Trust Corp grew its stake in shares of Cambrex by 0.7% during the 2nd quarter. Northern Trust Corp now owns 585,040 shares of the biotechnology company’s stock valued at $30,596,000 after acquiring an additional 4,104 shares during the period. Finally, Bank of Montreal Can grew its stake in shares of Cambrex by 26.8% during the 3rd quarter. Bank of Montreal Can now owns 71,769 shares of the biotechnology company’s stock valued at $4,909,000 after acquiring an additional 15,173 shares during the period.
A number of research analysts recently issued reports on CBM shares. Zacks Investment Research upgraded Cambrex from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a research note on Monday. TheStreet downgraded Cambrex from a “b” rating to a “c+” rating in a research note on Monday, December 3rd. Robert W. Baird assumed coverage on Cambrex in a research note on Thursday, November 15th. They issued an “outperform” rating for the company. ValuEngine upgraded Cambrex from a “strong sell” rating to a “sell” rating in a research note on Saturday, January 5th. Finally, First Analysis upgraded Cambrex from an “outperform” rating to a “strong-buy” rating and dropped their price target for the stock from $73.00 to $63.00 in a research note on Friday, November 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $60.83.
COPYRIGHT VIOLATION WARNING: This story was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.com-unik.info/2019/02/13/cambrex-co-cbm-position-raised-by-sg-americas-securities-llc.html.
Cambrex Company Profile
Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates.
Recommended Story: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.